Summary: Hepatocyte nuclear factor 4a (HNF4a) is an important transcription factor in hepatic gene expression. Here, we have investigated the role of HNF4a in the expression of drug-metabolizing enzymes and transporters in human hepatocytes using an adenovirus expressing human HNF4a-small interfering RNA (hHNF4a-siRNA). The hHNF4a-siRNA eŠectively reduced the mRNA and nuclear protein levels of hHNF4a in a concentration-dependent manner. The hHNF4a-siRNA also decreased the mRNA levels of CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGT1A1, UGT1A9, SULT2A1, ABCB1, ABCB11, ABCC2, OATP1B1 and OCT1, as well as those of PXR and CAR. To discern the role of these nuclear receptors, we co-infected hepatocytes with hHNF4a-siRNA and PXR-or CAR-expressing adenovirus. The hHNF4a-siRNA-induced reductions of the enzyme and transporter mRNA levels were not restored except CYP2B6 mRNA levels, which were returned to the control level by overexpressing CAR. Furthermore, although hHNF4a-siRNA did not signiˆcantly aŠect the fold-induction of CYP2B6, CYP2C8, CYP2C9, or CYP3A4 mRNA levels following treatment with CYP inducers, the levels in hHNF4a-suppressed cells fell signiˆcantly compared to the control. These results suggest that HNF4a plays a dominant role in the expression of drug-metabolizing enzymes and transporters in human hepatocytes, and that HNF4a expression levels is a possible determinant for interindividual variations in the expression of these enzymes and transporters.
Introduction
Hepatocyte nuclear factor 4a (HNF4a, NR2A1) is an orphan member of the nuclear receptor superfamily which is expressed in liver, kidney, intestine, and pancreas in mammals. 1, 2) This factor plays a critical role as a transcription factor in a wide variety of liver functions, including lipid and glucose metabolism. [3] [4] [5] [6] [7] In this regard, HNF4a gene is known to be associated with maturity-onset diabetes of the young. The mutation of this gene causes severe defects in insulin secretion. 8, 9) In addition to energy metabolism, HNF4a is involved in the metabolism of xenobiotics in the liver. [10] [11] [12] [13] Various drug-metabolizing enzymes and drug transporters such as cytochrome P450 (CYP), UDP-glucuronosyltransferase (UGT), sulfotransferase (SULT), ATP-binding cassette (ABC) transporter, and solute carrier (SLC) transporter play a major role in the metabolism and disposition of xenobiotics such as environmental contaminants and therapeutic drugs. In general, CYPs carry out the oxidative metabolism of lipophilic compounds, and UGTs and SULTs convert the compounds into more hydrophilic conjugates. Finally, ABC and SLC transporters pump these compounds out of the body.
Some of these genes are reported to undergo the regulation by HNF4a. 11, 14) In addition to HNF4a, various transcription factors such as pregnane X receptor (PXR), constitutive androstane receptor (CAR), and aryl hydrocarbon receptor (AhR) are known to regulate the expression of drug metabolism-related genes. 14) Generally, PXR, CAR, and AhR are considered to play key roles in the xenobiotic-induced expression of these genes, while HNF4a is necessary for their constitutive expression.
Given their well-established role in proving direct interactions between transcription factors and promoter sequences of target genes, investigations of the molecular mechanisms of speciˆc gene expression are often conducted using techniques including gel mobility shift assays, reporter gene assays and chromatin immunoprecipitation assays. These data provide information on the direct interactions between transcription factors and promoter sequences of target genes. The results obtained, however, do not necessarily re‰ect phenomena observed in vivo, partly owing to the use of artiˆcial gene constructs and overexpressed transcription factors. Moreover, the results sometimes also depend on the cell lines used. For example, human hepatoma HepG2 cells are often used to study the transcriptional regulation of genes encoding drug-metabolizing enzymes and transporters expressed abundantly in the liver, even though the expression levels of CYPs and liver-enriched transcription factors in HepG2 cells are markedly low compared with that in primary human hepatocytes. [15] [16] [17] Successful investigation of the mechanism of hepatic expression of drug-metabolizing enzyme and transporter genes thus depends on the selection of appropriate assay systems and cell lines.
Small interference RNA (siRNA) has been developed as a selective gene-knockdown technology to probe the function of a target gene. Although the transfection of synthetic siRNAs or siRNA expression plasmid-vectors often yields short-term suppression, and transfection e‹cacy depends on cell lines and transfection reagents, siRNA technology is increasingly used to clarify gene regulation mechanisms. To overcome these problems, we have developed an adenoviral vector system which enables the highly e‹cient transfection of various cell lines and tissues, especially liver cells. 18) In the present study, we have established an adenovirus vector expressing human HNF4a (hHNF4a)-siRNA which eŠectively suppresses hHNF4a expression in human hepatocytes. Here, we used this hHNF4a-siRNA-expressing adenovirus to investigate the speciˆc role of HNF4a in the gene expression of drugmetabolizing enzymes and transporters.
Materials and Methods

Materials
, dexamethazone (DEX) and rifampicin (RIF) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Phenobarbital sodium (PB) was obtained from Wako Pure Chemicals Industries, Ltd. (Osaka, Japan). William's E medium and penicillin-streptomycin were purchased from Invitrogen (Carlsbad, CA, USA). Matrigel and ITS-premix were from Becton Dickinson (Heidelberg, Germany). KHEM5310 medium was purchased from KAC Co., Ltd. (Kyoto, Japan). All other chemicals and reagents used were of analytical grade and purchased from commercial sources.
Recombinant adenoviruses: AdhHNF4a-siRNA: Human H1 gene promoter was used for the expression of siRNA. The H1 gene promoter was ampliˆed by PCR with the primers 5?-GCGAGATCTATTTGCATGT-CGCTATGTGTTCTGG-3? and 5?-GCGGAAGCT-TGTCGACGAGTGGTCTCATACAG-3?. The PCR product was digested with Bgl II and Sal I and cloned into the same restriction sites of the promoterless vector pShuttle (pShuttle-H1). hHNF4a-speciˆc siRNA designed by Takara (Ohtsu, Japan), which targets 5?-GAGATCCATGGTGTTCAAG-3?, was ampliˆed by PCR with primers 5?-CGCGTCGACGAGATCCAT-GGTGTTCAAGTTCAAGAGACT-3? and 5?-CGCA-AGCTTAAAAAAGAGATCCATGGTGTTCAAGT-CTCTTGAACT-3?, and the PCR product was digested with Sal I and HindIII and ligated into the same restriction sites of pShuttle-H1 (pShuttle-H1-hHNF4a-siRNA). Construction of an adenovirus expressing hHNF4a-siRNA (AdhHNF4a-siRNA) was performed with AdEasy TM System (MP Biomedicals, Irvine, CA, USA) according to the manufacturer's protocol.
AdhCAR: Human CAR (hCAR) cDNA was amplied by PCR with primers 5?-GCGGTCGACGTCATG-GCCAGTAGG-3? and 5?-CGCAAGCTTGGCCTCA-GCTGCAGATCTCC-3?. The PCR product was digested with Sal I and HindIII and ligated into the same restriction sites of pShuttle-CMV (pShuttle-CAR). The construction of an adenovirus expressing hCAR (Ad-hCAR) was performed with the AdEasy TM System. AdhPXR, an hPXR-expressing adenovirus, was reported previously. 19 ) AdCont (AxCALacZ), which expresses b-galactosidase, was provided by Dr. Izumi Saito (Tokyo University) and used as a control adenovirus. The titer of the recombinant adenovirus, 50z titer culture infection dose (TCID50) and multiplicity of infection (MOI) were determined as reported previously.
18)
Hepatocyte culture and infection of recombinant adenovirus: Cryopreserved human hepatocytes (lot. H582: Caucasian, female, 60 years old) were purchased from Xenotech LLC (Lenexa, KS, USA) and thawed using a Hepatocytes Isolation Kit (Xenotech LLC) according to the manufacturer's protocol. The cells were seeded onto collagen-coated 6-or 24-well plates (Becton Dickinson) at a density of 1.25×10 5 cells/cm 2 and maintained in KHEM5310 medium for 4-5 h in an atmosphere of 5z CO2/95z air at 379 C. After incubation, the medium was changed to serum-free Williams' E medium with 0.1 mM DEX, ITS-premix, 100 U/mL penicillin, 100 mg/mL streptomycin, and 50 mg/mL Matrigel, and cultured for 24 h in an atmosphere of 5z CO2/95z air at 379 C. The hepatocytes were incubated with 0.4 mL (6-well plate for nuclear extraction) and 0.1 mL (24-well plate for total RNA isolation) of the medium containing a recombinant adenovirus(es) for 1 h followed by the addition of 7.6 mL (6-well) or 1.9 mL (24-well) of medium and further cultured for 72 h. Forty-eight hours after the adenovirus infection, the hepatocytes were treated with 10 mM CITCO, 10 mM DEX, 1 mM PB, 10 mM RIF or vehicle (0.1z DMSO) for 24 h in CYP induction experiments. Quantitative Real-time PCR: Total RNA were isolated from the hepatocytes using an RNeasy } Mini Kit (QIAGEN, Valencia, CA, USA), and cDNA were prepared with random hexamer using ExScript } RT reagent Kit (Takara). To measure mRNA levels, quantitative real-time PCR was performed using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA) with TaqMan } Gene Expression Assays (Applied Biosystems) except HNF4a. HNF4a mRNA levels were determined with the following primers and probe: 5?-GAGGAACCAG-TGCCGCTACT-3?, 5?-TCTGGACGGCTTCCTTCT-TC-3? and 5?-FAM-AGAAATGCTTCCGGGCTGGC-TAMRA-3?. The mRNA levels were normalized against those of glyceraldehydes-3-phosphate dehydrogenase (GAPDH), which were determined with PreDeveloped TaqMan } Assay Reagents (Applied Biosystems).
Nuclear Extraction and Western Immunoblotting: Nuclear extracts were prepared from hepatocytes using a CelLytic TM NuCLEAR TM Extraction Kit (SigmaAldrich) according to the manufacturer's protocol and separated by 10z SDS-polyacrylamide gel electrophoresis (15 mg/lane). The proteins were transferred to a polyvinylidene di‰uoride membrane (Atto, Tokyo, Japan) and incubated sequentially with anti-hHNF4a antibody (Perseus Proteomics Inc., Tokyo, Japan) and horseradish peroxidase-conjugated anti-mouse IgG (GE Healthcare, Chalfont St Giles, UK). The signals were detected by chemiluminescence using the ECL Advance Western Blotting Detection kit (GE Healthcare). Protein concentrations were determined using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA) with bovine serum albumin as the standard.
Statistical analysis: Data were expressed as the mean±standard error (SEM) from four determinations. Statistical comparison of two groups was performed using two-tailed Student's t-test, and those of multiple groups were performed using one-way ANOVA followed by Dunnett's post hoc test. P values less than 0.05 were considered statistically signiˆcant.
Results
Inhibition of hHNF4a function by AdhHNF4a-siRNA infection: To evaluate the e‹cacy of AdhHNF4a-siRNA, human hepatocytes were infected with AdhHNF4a-siRNA, and then the mRNA and nuclear protein levels of hHNF4a were determined. The mRNA levels were decreased in an AdhHNF4a-siRNA concentration-dependent manner (MOI: 0.04-4), with an approximately 60z decrease compared with the AdCont-infected cells observed at an MOI of 4 (Fig. 1A) . Consistently, Western blotting analysis of the nuclear extracts from human hepatocytes revealed a decrease in hHNF4a protein levels by AdhHNF4a-siRNA infection in a concentration-dependent manner (MOI: 0.04-4), with an approximately 80z decrease compared with the AdCont-infected cells observed at an MOI of 4 (Fig. 1B) . To examine the consequences of the reduced hHNF4a expression, we next determined the mRNA levels of apolipoprotein C-III (ApoCIII) and ornithine transcarbamylase (OTC), typical target genes of HNF4a. 20, 21) As expected, both mRNA levels were decreased as the hHNF4a mRNA levels, indicating that functional HNF4a levels were decreased in hepatocytes infected with AdhHNF4a-siRNA ( Fig. 1C and data not  shown) .
EŠects of reduced hHNF4a levels on the expression of CYPs: To investigate the eŠects of reduced hHNF4a function on various drug-metabolizing CYPs, mRNA levels were determined in human hepatocytes infected with various amounts of AdhHNF4a-siRNA (Fig. 2) . Among the CYPs examined, the mRNA levels of CYP2A6 and CYP3A4 showed the greatest decrease and were 15z and 19z that of AdCont-infected cells at an MOI of 4, respectively. The extent of these decreases was greater than those for ApoCIII and OTC. In addition, the mRNA levels of CYP2B6, CYP2C8, CYP2C9, and CYP2D6 were also decreased, but to a modest , and cultured for 72 h. A. cDNA were prepared from hepatocytes and hHNF4a mRNA levels were determined by quantitative real-time PCR analysis as described in Materials and Methods. B. Nuclear extracts were prepared from hepatocytes and Western blot analysis was performed to determine hHNF4a protein levels as described in Materials and Methods. Molecular weights are shown on the right. C. ApoCIII mRNA levels were determined by quantitative real-time PCR analysis. hHNF4a and ApoCIII mRNA levels were normalized with those of GAPDH, and those in AdCont-infected cells are set at 1. Data are expressed as the mean±SEM of four samples. **, pº0.01; statistically signiˆcant from AdCont-infected cells.
extent, and comparable to those of ApoCIII and OTC. The mRNA levels of CYP2C19 were decreased and the extent of this decrease was lower than those of ApoCIII and OTC. In contrast, no signiˆcant eŠects were observed on CYP1A1 and CYP2J2 mRNA levels.
EŠects of reduced hHNF4a levels on the expression of transcription factors: We next determined mRNA levels of transcription factors known to be involved in CYP expression after infection with AdhHNF4a-siRNA. As shown in Fig. 3 , signiˆcant degrease in PXR and CAR mRNA levels were observed, to 54z and 41z of control cells, respectively, at an MOI of 4. In contrast, no change in AhR mRNA levels was observed.
Possible role of PXR and CAR in the basal expression of CYPs: Introduction of hHNF4a siRNA resulted in the attenuation of PXR and CAR expression in human hepatocytes. Since these nuclear receptors are known to regulate the expression of CYP2B6, CYP2C8, CYP2C9, and CYP3A4 genes, we therefore investigated whether the reduced basal expression of these genes was attributable to the diminution of PXR or CAR expression. To this end, human hepatocytes were infected with an adenovirus expressing hPXR or hCAR in combination with AdhHNF4a-siRNA, after which mRNA levels of CYP2B6, CYP2C8, CYP2C9, and CYP3A4 were determined. When the cells were infected with AdhPXR/AdhCAR in the presence of AdhHNF4a-siRNA, the hHNF4a mRNA levels did not change (Fig. 4A) . AdPXR infection with AdhHNF4a-siRNA returned PXR mRNA levels to 120z and 125z of those of the control cells at an MOI of 1 and 2, respectively, without aŠecting CAR mRNA levels (Fig. 4A) . Similarly, infection of AdhCAR with AdhHNF4a-siRNA increased CAR mRNA levels to 300z and 420z of those of control cells at an MOI of 1 and 2, respectively, and did not change PXR mRNA levels (Fig. 4A) . In these conditions, CYP2B6 mRNA levels were returned to control levels by infection with AdhCAR, but not with AdhPXR (Fig. 4B) . In contrast, the mRNA levels of CYP2C8, CYP2C9, and CYP3A4 remained attenuated even when hPXR or hCAR was overexpressed (Fig.  4B) .
EŠects of hHNF4a suppression on the xenobioticinduced expression of CYP2B6, CYP2C8, CYP2C9, and CYP3A4: To assess the contribution of hHNF4a to CYP induction by xenobiotics, the mRNA levels of CYP2B6, CYP2C8, CYP2C9, and CYP3A4 were determined in human hepatocytes treated with various CYP inducers including CITCO, PB, RIF, or DEX with or without AdhHNF4a-siRNA infection (Fig. 5) . None Fig. 2 . EŠects of hHNF4a-downregulation on CYP mRNA levels in human hepatocytes. Human hepatocytes were infected with control adenovirus AdCont (MOI of 4) or AdhHNF4a-siRNA (MOI of 0.04, 0.12, 0.4, 1.2, or 4) and cultured for 72 h. CYP mRNA levels were determined by quantitative real-time PCR analysis, and were normalized with those of GAPDH. mRNA levels in AdCont-infected cells are set at 1. Data are expressed as the mean±SEM of four samples. *, pº0.05; **, pº0.01; statistically signiˆcant from AdCont-infected cells. Fig. 3 . EŠects of hHNF4a-downregulation on mRNA levels of PXR, CAR, and AhR in human hepatocytes. Quantitative real-time PCR analyses were performed as in Fig. 2 . mRNA levels of transcription factors were normalized with those of GAPDH. mRNA levels in AdCont-infected cells are set at 1. Data are expressed as the mean±SEM of four samples. *, pº0.05; **, pº0.01; statistically signiˆcant from AdCont-infected cells.
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Utility of Human HNF4a-siRNA of the inducers used aŠected hHNF4a mRNA levels (Fig. 5A) , and none of the CYP mRNA levels were changed by DEX treatment in either AdCont-or AdhHNF4a-siRNA-infected cells (Fig. 5B) .
As shown in Fig. 5B , CYP2B6 mRNA levels were increased by treatment with the hCAR activators CITCO and PB, as well as by treatment with the hPXR ligand RIF. These increases in CYP2B6 mRNA levels by chemical treatment were also observed after infection with AdhHNF4a-siRNA, although the mRNA levels were much lower than those in cells infected with control virus.
CYP2C8 mRNA levels were increased 3.0-and 2.2-fold by treatment with PB and RIF, respectively, in AdCont-infected cells. These chemicals slightly increased the mRNA levels in hepatocytes infected with AdhHNF4a-siRNA, but their levels were similar to those in control virus-infected, vehicle-treated cells (Fig. 5C) .
Similar results were obtained for CYP2C9 and CYP3A4 mRNA levels for both were increased 1.4-to 4.5-fold by treatment with CITCO, PB, or RIF, in AdCont-infected cells. Similarly, these increases in mRNA levels were observed after infection with AdhHNF4a-siRNA, although the levels were signiˆcantly lower than those in cells infected with control adenovirus (Fig. 5C) .
Role of hHNF4a in the expression of phase II drugmetabolizing enzymes and drug transporters: Recent studies have demonstrated that the gene expression of phase II drug-metabolizing enzymes and transporters in hepatocytes is regulated by mechanisms similar to those for CYP genes. On this basis, we investigated the eŠects of reduced hHNF4a expression on the mRNA levels of various phase II enzymes and transporters. As shown in Figs. 6A and 6B, signiˆcant decreases in UGT1A1, SULT2A1, ABCB11, ABCC2, OATP1B1, and OCT1 mRNA levels were observed after infection with AdhHNF4a-siRNA. The mRNA levels of UGT1A9 and ABCB1 were also decreased at an MOI of 4, although they were slightly increased at a lower MOI. In contrast, no signiˆcant changes in UGT1A6 mRNA levels were Fig. 4 . CYP2B6, CYP2C8, CYP2C9, and CYP3A4 mRNA levels in human hepatocytes co-infected with AdhHNF4a-siRNA and PXR-or CARexpressing adenovirus. Human hepatocytes were infected with control adenovirus AdCont or AdhHNF4a-siRNA, with or without PXR or CAR expression adenovirus, and cultured for 72 h. Quantitative real-time PCR analyses were performed to determine mRNA levels of hHNF4a, PXR, CAR (A), CYP2B6, CYP2C8, CYP2C9, and CYP3A4 (B). Data are expressed as the mean±SEM of four samples. * , pº0.05; ** , pº0.01; statistically signiˆcant from AdCont-infected cells. Fig. 5 . EŠects of hHNF4a suppression on the xenobiotic-induced expression of CYP2B6, CYP2C8, CYP2C9, and CYP3A4 in human hepatocytes. Human hepatocytes were infected with control adenovirus AdCont (open box) or AdhHNF4a-siRNA (closed box) at an MOI of 4. Forty-eight hours after infection, the cells were treated with 10 mM CITCO, 1 mM PB, 10 mM RIF, 10 mM DEX, or vehicle (0.1z DMSO) for 24 h. Quantitative real-time PCR analyses were performed to determine mRNA levels of hHNF4a (A) and CYPs (B). Fold-induction by xenobiotics is shown in C. Data are expressed as the mean±SEM of four samples. *, pº0.05; **, pº0.01; statistically signiˆcant from AdCont-infected cells with the same treatment by Student's t-test (A and B) . †, pº0.05; † †, pº0.01; statistically signiˆcant from vehicle treated cells infected with the same adenovirus by Student's t-test (B).
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Utility of Human HNF4a-siRNA observed (Fig. 6A) . We next investigated whether the reduced basal expression of UGT1A1, UGT1A9, SULT2A1, ABCB11, ABCC2, OTAP1B1 and OCT1 were attributable to the diminution of PXR or CAR expression. As shown in Figs. 6C and 6D , the mRNA levels of UGT1A1, UGT1A9, SULT2A1, ABCB11, ABCC2, OATP1B1 and OCT1 remained attenuated even when hPXR or hCAR was overexpressed as CYP2C8, CYP2C9, and CYP3A4.
Discussion
The adenoviral vector system enables us to express target genes in various cell lines, especially in liver cells, with high e‹ciency and is applicable to both experimental animals and humans. In this study, we examined the role of HNF4a in expression of drug-metabolizing enzymes and drug transporters in human hepatocytes. To this end, we have constructed an adenovirus expressing hHNF4a-siRNA. Transfection of mammalian cells with a double-stranded RNA with a length of more than approximately 30 bp often causes cell death because apoptosis is triggered by double-stranded RNA-induced interferon response. [22] [23] [24] [25] Therefore, we have used 19-bp siRNA for hHNF4a knock-down in this study. Results showed that AdhHNF4a-siRNA infection suppressed hHNF4a expression at both mRNA and nuclear protein levels in human hepatocytes in a dose-dependent manner. At an MOI of 4, the nuclear protein levels of hHNF4a were approximately 20z of AdCont-infected cells. Further, the mRNA levels of ApoCIII and OTC, typical target genes of hHNF4a, were decreased to a degree comparable to that of hHNF4a. These results demonstrate the e‹cacy and speciˆcity of our hHNF4a-siRNA expression adenovirus in human hepatocytes.
HNF4a has been proposed to regulate various human drug-metabolizing enzymes and transporters including CYP2A6, CYP2C8, CYP2C9, CYP2D6, CYP3A4, UGT1A9 and OCT1 in cell-line based assays. 11, 12, [26] [27] [28] [29] [30] [31] It has also been reported that ABCC2 is regulated by HNF4a via a hepatocyte nuclear factor-1-dependent mechanism. 32) In addition, the suppression of hHNF4a expression using this adenovirus aŠected the expression of various drug-metabolizing enzymes and transporters, including CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGT1A1, UGT1A9, SULT2A1, ABCB1, ABCB11, ABCC2, OATP1B1, and OCT1, in human hepatocytes. Among these, CYP2A6 and CYP3A4 were decreased the most. Recently, Jover et al. 33) have reported that HNF4a regulates the expression of several CYP genes such as CYP2A6, CYP2B6, CYP2C9, CYP2D6, and CYP3A4 in human hepatocytes using an antisense technique. Our results obtained with diŠerent techniques are in good agreement with their results (Fig. 2) . Moreover, we quantitatively showed the correlation between the suppression of hHNF4a mRNA levels and those of CYPs, phase II enzymes and transporters by use of hHNF4a-siRNAexpressing adenovirus. From the results, we categorized the drug-metabolizing enzymes and transporters into four groups: Group 1: CYP2A6 and CYP3A4, whose mRNA levels were decreased much more than that of hHNF4a; Group 2: CYP2B6, CYP2C8, CYP2C9, CYP2D6, UGT1A1, SULT2A1, ABCB11, and OCT1, whose mRNA levels were decreased to an extent similar to that of hHNF4a; Group 3: CYP2C19, UGT1A9, ABCB1, ABCC2, and OATP1B1, whose mRNA levels were decreased to an extent less than that of hHNF4a; Group 4: CYP1A1, CYP2J2, and UGT1A6, whose mRNA levels did not change. The reason why the suppression of CYP2A6 and CYP3A4 mRNA levels was greater than those of HNF4a target genes, ApoCIII and OTC, remains unknown but we assume that the expressions of CYP2A6 and CYP3A4 genes might be regulated not only by HNF4a but also by the multiple transcriptional factors of which expressions are regulated by HNF4a.
In the present study, we found that the mRNA levels of PXR and CAR, but not AhR, were also decreased with AdhHNF4a-siRNA infection in similar proportion to that of hHNF4a. These results support the idea that the expression of PXR and CAR is regulated by HNF4a in human hepatocytes, as was proposed in the previous reports on the HNF4a-dependent expression of PXR and CAR. 10, 31, 34) We thus investigated the possibility that the down-regulation of CYP2B6, CYP2C8, CYP2C9, and CYP3A4 genes after AdhHNF4a-siRNA was due to the reduced expression levels of PXR/CAR, using an adenovirus expressing hPXR or hCAR in combination with AdhHNF4a-siRNA. Results showed that the only mRNA levels of CYP2B6 were returned to control levels after the infection with AdhCAR. In contrast, those of CYP2C8, CYP2C9, and CYP3A4 remained attenuated. In the same way, mRNA levels of phase II enzymes (UGT1A1, UGT1A9, and SULT2A1) and transporters (ABCB11, ABCC2, OATP1B1, and OCT1) also remained attenuated even with hPXR or hCAR overexpression. Although further conˆrmation is necessary, these results suggest that the basal expression of CYP2B6 is indirectly regulated by hHNF4a via a CARmediated mechanism, whereas those of other CYPs, phase II enzymes and transporters are directly regulated by hHNF4a. Alternatively, because PXR and CAR are activated or inhibited by endogenous ligands such as steroids and bile acids, 35, 36) these nuclear receptors may regulate the basal expression of drug-metabolizing enzymes and transporters by endogenous ligands under cooperation with hHNF4a.
Although the mRNA levels of CYP2B6, CYP2C8, CYP2C9, and CYP3A4 were decreased in human hepatocytes infected with hHNF4a-siRNA adenovirus, treatment with typical CYP inducers increased these levels to a similar degree as in control adenovirus-infected cells, suggesting that the role of HNF4a in the xenobiotic-mediated induction of CYPs is minimal. These results are inconsistent with recent results demonstrating that hHNF4a cooperates with PXR, CAR or both during the transcription of CYP genes. 27, 29, 37) The reason for this discrepancy remains unknown, but it may be due to the partial down-regulation of these nuclear receptors in our system. Nevertheless, the mRNA levels of CYP2B6, CYP2C8, CYP2C9, and CYP3A4 under the hHNF4a-suppressed conditions and in the presence of CYP inducers were either closely similar to or markedly lower than those in control cells. This strongly suggests that HNF4a plays a dominant role in determing the expression levels of drugmetabolizing enzyme and transporter genes in human hepatocytes.
The inter-individual diŠerences in the expression levels and activities of drug-metabolizing enzymes are well-known phenomena. [38] [39] [40] Our present results have raised the possibility that the mRNA levels of drugmetabolizing enzymes and transporters are in‰uenced by the expression level of hHNF4a. To date, no report has been published on the interindividual variations of HNF4a expression levels in human livers. Interestingly, mutations in the hHNF4a gene, that reduce its ability to function, have been found to cause the maturity-onset diabetes of the young, non insulin dependent diabetes mellitus with severe insulin secretion defects. 8, 9) Thus, it is of interest to examine the hepatic expression of individual drug-metabolizing enzymes and transporters in these patients. Furthermore, studies focused on the genetic polymorphism of HNF4a may provide an additional insight into the role of HNF4a in the drug metabolism and disposition in humans.
In conclusion, we have demonstrated the fundamental role of HNF4a in the gene expression of drugmetabolizing enzymes and drug transporters in human hepatocytes by use of a combination of hHNF4a siR-NA-expressing adenovirus and PXR-or CAR-expressing adenovirus. These results indicate that the siRNAexpressing adenovirus system is a very useful technique for studying the gene expression mechanisms of drugmetabolizing enzymes and transporters, which will provide a valuable mechanistic insight into the interindividual variations.
